FINHUB Insights

LLY · Q3 FY25 · Jul 1 – Sep 30, 2025

Eli Lilly Q3 FY25: where the revenue came from and where it went

Eli Lilly Q3 FY25: revenue $17.6B (+54% year over year). Net profit $5.6B. Largest cohort Mounjaro $6.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Oct 30, 2025 10-Q
Sankey diagram of Eli Lilly's income statement for Q3 FY25: revenue of $17.6 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$17.6B +54% year over year
Gross profit$14.6B 83% margin
Operating profit$7.4B 42% margin
Net profit$5.6B 32% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 17.6 100% +54%
Mounjaro 6.5 37% +109%
Zepbound 3.6 20% +185%
Other 2 11%
Verzenio 1.5 9% +7%
Other Cardiometabolic Health 1.1 6% +1%
Trulicity 1.1 6% −19%
Jardiance 1 6% +40%
Other Oncology 0.9 5% +9%
Cost of revenue−317%
Gross profit14.683% margin+2pp
SG&A−2.716%−3pp
Other−4.525%+0pp
Operating profit7.442% margin+29pp
Tax−1.7
Interest & other costs−0.1
Net profit5.632%+23pp
Filing on EDGAR More quarters of LLY

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters